Patents by Inventor Bodo Betzemeier

Bodo Betzemeier has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Crystalline salts of a B-RAF kinase inhibitor
    Patent number: 11753409
    Abstract: The present invention is related to crystalline salts of N-(3-(5-((1-ethylpiperidin-4-yl)(methyl)amino)-3-(pyrimidin-5-yl)-1H-pyrrolo[3,2-b]pyridin-1-yl)-2,4-difluorophenyl)propane-1-sulfonamide, a RAF kinase Inhibitor, useful in the treatment of cancer and other diseases.
    Type: Grant
    Filed: March 11, 2022
    Date of Patent: September 12, 2023
    Assignee: Xynomic Pharmaceuticals, Inc.
    Inventors: Ulrike Werthmann, Gerd-Michael Maier, Bodo Betzemeier, Otmar Schaaf
  • CRYSTALLINE SALTS OF A B-RAF KINASE INHIBITOR
    Publication number: 20220204506
    Abstract: The present invention is related to crystalline salts of N-(3-(5-((1-ethylpiperidin-4-yl)(methyl)amino)-3-(pyrimidin-5-yl)-1H-pyrrolo[3,2-b]pyridin-1-yl)-2,4-difluorophenyl)propane-1-sulfonamide, a RAF kinase Inhibitor, useful in the treatment of cancer and other diseases.
    Type: Application
    Filed: March 11, 2022
    Publication date: June 30, 2022
    Inventors: Ulrike Werthmann, Gerd-Michael Maier, Bodo Betzemeier, Otmar Schaaf
  • Crystalline salts of a B-RAF kinase inhibitor
    Patent number: 11306086
    Abstract: The present invention is related to crystalline salts of N-(3-(5-((1-ethylpiperidin-4-yl)(methyl)amino)-3-(pyrimidin-5-yl)-1H-pyrrolo[3,2-b]pyridin-1-yl)-2,4-difluorophenyl)propane-1-sulfonamide, a RAF kinase Inhibitor, useful in the treatment of cancer and other diseases.
    Type: Grant
    Filed: October 26, 2018
    Date of Patent: April 19, 2022
    Assignee: Xynomic Pharmaceuticals, Inc.
    Inventors: Ulrike Werthmann, Gerd-Michael Maier, Bodo Betzemeier, Otmar Schaaf
  • MEDICAL USE OF COMPOUND III
    Publication number: 20210130362
    Abstract: The present invention relates to compound III and its use for treatment and/or prevention of diseases of the schizophrenia spectrum and other psychotic disorders, first episodes of these diseases such as first episode of psychosis (FEP), relapses of these diseases such as reduction of relapse in patients with schizophrenia (REX). The invention also relates to polymorphs of compound III, and pharmaceutical compositions comprising compound III and/or its polymorphs.
    Type: Application
    Filed: January 11, 2021
    Publication date: May 6, 2021
    Inventors: Michael Steven SAND, Holger ROSENBROCK, Riccardo GIOVANNINI, Masashi ADACHI, Bodo BETZEMEIER, Tobias BRODMANN, Takayuki KAMATA, Yohei KAWABATA, Masanori ITO, Daniel MARCKART, Manabu NAKATANI, Ulrike WERTHMANN
  • Medical use of compound III
    Patent number: 10919898
    Abstract: The present invention relates to compound III and its use for treatment and/or prevention of diseases of the schizophrenia spectrum and other psychotic disorders, first episodes of these diseases such as first episode of psychosis (FEP), relapses of these diseases such as reduction of relapse in patients with schizophrenia (REX). The invention also relates to polymorphs of compound III, and pharmaceutical compositions comprising compound III and/or its polymorphs.
    Type: Grant
    Filed: February 21, 2018
    Date of Patent: February 16, 2021
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Michael Steven Sand, Holger Rosenbrock, Riccardo Giovannini, Masashi Adachi, Bodo Betzemeier, Tobias Brodmann, Takayuki Kamata, Yohei Kawabata, Masanori Ito, Daniel Marckart, Manabu Nakatani, Ulrike Werthmann
  • CRYSTALLINE SALTS OF A B-RAF KINASE INHIBITOR
    Publication number: 20200283433
    Abstract: The present invention is related to crystalline salts of N-(3-(5-((1-ethylpiperidin-4-yl)(methyl)amino)-3-(pyrimidin-5-yl)-1H-pyrrolo[3,2-b]pyridin-1-yl)-2,4-difluorophenyl)propane-1-sulfonamide, a RAF kinase Inhibitor, useful in the treatment of cancer and other diseases.
    Type: Application
    Filed: October 26, 2018
    Publication date: September 10, 2020
    Inventors: Ulrike Werthmann, Gerd-Michael Maier, Bodo Betzemeier, Otmar Schaaf
  • Medical Use of Compound III
    Publication number: 20180237445
    Abstract: The present invention relates to compound III and its use for treatment and/or prevention of diseases of the schizophrenia spectrum and other psychotic disorders, first episodes of these diseases such as first episode of psychosis (FEP), relapses of these diseases such as reduction of relapse in patients with schizophrenia (REX). The invention also relates to polymorphs of compound III, and pharmaceutical compositions comprising compound III and/or its polymorphs.
    Type: Application
    Filed: February 21, 2018
    Publication date: August 23, 2018
    Inventors: Michael Steven SAND, Holger ROSENBROCK, Riccardo GIOVANNINI, Masashi ADACHI, Bodo BETZEMEIER, Tobias BRODMANN, Takayuki KAMATA, Yohei KAWABATA, Masanori ITO, Daniel MARCKART, Manabu NAKATANI, Ulrike WERTHMANN
  • Pyrimidine derivatives that inhibit FAK/PTK2
    Patent number: 8785464
    Abstract: The present invention includes compounds of general formula (1) wherein A, X, R1 and R2 are defined as in claim 1, which are suitable for the treatment of diseases characterized by excessive or abnormal cell proliferation, and their use for preparing a medicament having the above-mentioned properties.
    Type: Grant
    Filed: October 9, 2013
    Date of Patent: July 22, 2014
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Heinz Stadtmueller, Bodo Betzemeier, Ioannis Sapountzis
  • NEW COMPOUNDS
    Publication number: 20140038993
    Abstract: The present invention includes compounds of general formula (1) wherein A, X, R1 and R2 are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and their use for preparing a medicament having the above-mentioned properties.
    Type: Application
    Filed: October 9, 2013
    Publication date: February 6, 2014
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Heinz STADTMUELLER, Bodo BETZEMEIER, Ioannis SAPOUNTZIS
  • CRYSTALLINE FORM OF A INDOLINONE DERIVATIVE AND ITS USE
    Publication number: 20140018372
    Abstract: A crystalline form of 3-{3-[1-(4-Dimethylaminomethyl-phenylamino)-1-phenyl-meth-(Z)-ylidene]-2-oxo-2,3-dihydro-1H-indol-6-yl}-propynoic acid ethylamide.
    Type: Application
    Filed: July 9, 2013
    Publication date: January 16, 2014
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Gerd-Michael MAIER, Anke BAUM, Bodo BETZEMEIER, Manuel HENRY, Rolf HERTER, Ulrich REISER, Patrizia SINI, Dirk WEBER, Ulrike WERTHMANN, Stephan Karl ZAHN
  • 2,4-diaminopyrimidine derivates as PTK2-inhibitors for the treatment of abnormal cell growth
    Patent number: 8377943
    Abstract: The present invention encompasses compounds of general formula (1) wherein R1-R3 and n are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and their use for preparing a medicament having the above-mentioned properties.
    Type: Grant
    Filed: November 13, 2009
    Date of Patent: February 19, 2013
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Ioannis Sapountzis, Bodo Betzemeier, Heinz Stadtmueller
  • Substituted indolines as tyrosine kinase inhibitors
    Patent number: 8207179
    Abstract: The present invention encompasses compounds of general Formula (1) wherein R2, R3, Q, W, X, Y and Z are defined as in claim 1, which are suitable for the treatment of diseases characterized by excessive or abnormal cell proliferation, and the use thereof for preparing a medicament having the above-mentioned properties.
    Type: Grant
    Filed: June 9, 2008
    Date of Patent: June 26, 2012
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Harald Engelhardt, Bodo Betzemeier, Guido Boehmelt, Ulrich Guertler, Thomas Karner, Oliver Kraemer, Daniel Kuhn, Jens Juergen Quant, Ulrich Reiser, Otmar Schaaf, Flavio Solca, Heinz Stadtmueller, Ulrike Tontsch-Grunt, Matthias Treu, Stephan Karl Zahn
  • Thiazolyl-dihydro-indazoles
    Patent number: 8207349
    Abstract: The present invention encompasses compounds of the general formula (1) in which R1 to R3 are defined as in claim 1, which are suitable for treating diseases which are characterized by excessive or anomalous cell proliferation, and their use for producing a pharmaceutical having the abovementioned properties.
    Type: Grant
    Filed: January 11, 2010
    Date of Patent: June 26, 2012
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Bodo Betzemeier, Trixi Brandl, Steffen Breitfelder, Ralph Brueckner, Thomas Gerstberger, Michael Gmachl, Matthias Grauert, Frank Hilberg, Christoph Hoenke, Matthias Hoffmann, Maria Impagnatiello, Dirk Kessler, Christian Klein, Bernd Krist, Udo Maier, Darryl McConnell, Charlotte Reither, Stefan Scheuerer, Andreas Schoop, Norbert Schweifer, Oliver Simon, Martin Steegmaier, Steffen Steurer, Irene Waizenegger, Ulrike Weyer-Czernilofsky, Andreas Zoephel
  • NEW COMPOUNDS
    Publication number: 20110288109
    Abstract: The present invention includes compounds of general Formula (1), wherein A, X, R1 and R2 are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and their use for preparing a medicament having the above-mentioned properties.
    Type: Application
    Filed: November 24, 2009
    Publication date: November 24, 2011
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Heinz Stadtmueller, Bodo Betzemeier, Ioannis Sapountzis
  • 2,4-DIAMINOPYRIMIDINE DERIVATES AS PTK2- INHIBITORS FOR THE TREATMENT OF ABNORMAL CELL GROWTH
    Publication number: 20110275633
    Abstract: The present invention encompasses compounds of general formula (1) wherein R1-R3 and n are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and their use for preparing a medicament having the above-mentioned properties.
    Type: Application
    Filed: November 13, 2009
    Publication date: November 10, 2011
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Ioannis Sapountzis, Bodo Betzemeier, Heinz Stadtmueller
  • Thiazolyl-dihydro-indazole
    Patent number: 7902183
    Abstract: The present invention encompasses compounds of general formula (1) wherein R1 to R5 are defined as in claim 1, which are suitable for the treatment of diseases characterized by excessive or abnormal cell proliferation, and the use thereof for preparing a medicament having the above-mentioned properties.
    Type: Grant
    Filed: April 5, 2007
    Date of Patent: March 8, 2011
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Steffen Steurer, Bodo Betzemeier, Darryl McConnell, Thomas Gerstberger, Matthias Grauert, Matthias Hoffmann, Maria Impagnatiello, Lars van der Veen, Ulrike Weyer-Czernilofsky
  • Thiazolyl-dihydro-indazole
    Patent number: 7893049
    Abstract: The present invention encompasses compounds of general formula (1) wherein R1 to R6 are defined as in claim 1, which are suitable for the treatment of diseases characterized by excessive or abnormal cell proliferation, and the use thereof for preparing a medicament having the above-mentioned properties.
    Type: Grant
    Filed: April 5, 2007
    Date of Patent: February 22, 2011
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Darryl McConnell, Bodo Betzemeier, Thomas Gerstberger, Maria Impagnatiello, Steffen Steurer, Lars van der Veen, Ulrike Weyer-Czernilofsky
  • NEW COMPOUNDS
    Publication number: 20100222331
    Abstract: The present invention encompasses compounds of general Formula (1) wherein R2, R3, Q, W, X, Y and Z are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and the use thereof for preparing a medicament having the above-mentioned properties.
    Type: Application
    Filed: June 9, 2008
    Publication date: September 2, 2010
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Harald Engelhardt, Bodo Betzemeier, Guido Boehmelt, Ulrich Guertler, Thomas Karner, Oliver Kraemer, Daniel Kuhn, Jens Juergen Quant, Ulrich Reiser, Otmar Schaaf, Flavio Solca, Heinz Stadtmueller, Ulrike Tontsch-Grunt, Matthias Treu, Stephan Karl Zahn
  • THIAZOLYL-DIHYDRO-INDAZOLES
    Publication number: 20100113414
    Abstract: The present invention encompasses compounds of the general formula (1) in which R1 to R3 are defined as in claim 1, which are suitable for treating diseases which are characterized by excessive or anomalous cell proliferation, and their use for producing a pharmaceutical having the abovementioned properties.
    Type: Application
    Filed: January 11, 2010
    Publication date: May 6, 2010
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Bodo BETZEMEIER, Trixi BRANDL, Steffen BREITFELDER, Ralph BRUECKNER, Thomas GERSTBERGER, Michael GMACHL, Matthias GRAUERT, Frank HILBERG, Christoph HOENKE, Matthias HOFFMANN, Maria IMPAGNATIELLO, Dirk KESSLER, Christian KLEIN, Bernd KRIST, Udo MAIER, Darryl McCONNELL, Charlotte REITHER, Stefan SCHEUERER, Andreas SCHOOP, Norbert SCHWEIFER, Oliver SIMON, Martin STEEGMAIER, Steffen STEURER, Irene WAIZENEGGER, Ulrike WEYER-CZERNILOFSKY, Andreas ZOEPHEL
  • Thiazolyl-dihydro-indazole
    Patent number: 7691888
    Abstract: The present invention encompasses compounds of the general formula (1) in which R1 to R3 are defined as in claim 1, which are suitable for treating diseases which are characterized by excessive or anomalous cell proliferation, and their use for producing a pharmaceutical having the abovementioned properties.
    Type: Grant
    Filed: October 5, 2005
    Date of Patent: April 6, 2010
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Bodo Betzemeier, Trixi Brandl, Steffen Breitfelder, Ralph Brueckner, Thomas Gerstberger, Michael Gmachl, Matthias Grauert, Frank Hilberg, Christoph Hoenke, Matthias Hoffmann, Maria Impagnatiello, Dirk Kessler, Christian Klein, Bernd Krist, Udo Maier, Darryl McConnell, Charlotte Reither, Stefan Scheuerer, Andreas Schoop, Norbert Schweifer, Oliver Simon, Martin Steegmaier, Steffen Steurer, Irene Waizenegger, Ulrike Weyer-Czernilofsky, Andreas Zoephel